Samsung Biologics' First-Ever Strike Halts Cancer-Drug Output, Company Cites ₩150 Billion Loss

TL;DR - Samsung Biologics, the world's largest biologics contract manufacturer by capacity, faces the first full-scale strike in its 15-year history, with about 2,800 of roughly 4,000 union members walking out on May 1. - The company tells local media the work stoppage has already caused ₩150 billion ($110 million) in losses and forced suspension of certain cancer- and HIV-drug batches. - Mediated talks resume this weekend; the gap between the union's 14% wage demand and management's 6.2% offer remains the central obstacle.

Lead

Samsung Biologics (207940.KS), South Korea's flagship biologics contract development and manufacturing organization (CDMO), is contending with the first general strike since its 2011 founding, with the walkout entering a second day on May 2. The company said in a statement carried by Yonhap News Agency that losses had already reached roughly ₩150 billion ($110 million) as some production lines went dark, including batches tied to oncology and HIV therapies. Management and the union are scheduled to resume mediation under the Central Regional Employment and Labor Office after thirteen prior bargaining rounds failed to close the gap.

What Happened

The Samsung Biologics labor union, which according to The Korea Herald represents about 4,000 of the company's roughly 5,455 employees, launched a five-day full-scale strike on May 1, Korea's Labor Day, with action planned through May 5. About 2,800 members — roughly 70% of the union — joined the first day of the walkout, principally by taking collective annual leave and refusing scheduled shifts at the company's Songdo bio campus in Yeonsu-gu, Incheon, according to Maeil Business Newspaper and Seoul Economic Daily.

The company issued a statement on May 1 acknowledging the disruption and pledging to "approach the resolution with a sense of responsibility," Yonhap reported. By the morning of May 2, Samsung Biologics confirmed in a follow-up statement carried by Maeil Business Newspaper that approximately ₩150 billion in losses had accumulated and that some manufacturing processes — including suspended batches of cancer and HIV treatments — had been halted despite the redeployment of available non-union staff. Samsung Biologics has separately estimated that a fully realized walkout could generate up to ₩640 billion ($470 million) in losses, according to Seoul Economic Daily.

A local court has partially restricted strike activity at three of nine production stages identified as essential, while permitting industrial action at the remaining six, per The Korea Herald.

Why It Matters

This is the first concrete signal that the labor peace which has accompanied Samsung Biologics' decade-long ascent to global CDMO leadership can no longer be taken for granted. The company has gone strike-free since its 2011 incorporation — a 15-year stretch repeatedly cited by The Korea Herald and Seoul Economic Daily — even as headcount, capacity, and contract value scaled rapidly. A multi-day production interruption at a CDMO is unusually costly because biologic batches that lose tight process control during fermentation must typically be discarded, a point Seoul Economic Daily highlighted in describing why ₩150 billion accrued so quickly. For multinational pharma clients that depend on Songdo for commercial supply of antibodies and other biologics, the dispute introduces a supply-chain variable they have not previously had to model.

Business Impact

Samsung Biologics reported Q1 2026 revenue of ₩1,257.1 billion (about $917 million) and operating profit of ₩580.8 billion (about $424 million), up 25.8% and 35.0% year-over-year respectively, according to the company's PR Newswire release. The company attributed the result to "full utilization across Plants 1 through 4" with Plant 5 ramp-up underway, and disclosed cumulative contract value above $21.4 billion.

Against that revenue base, the ₩150 billion strike-related loss disclosed to Yonhap and Maeil Business Newspaper through May 2 equates to roughly 12% of a single quarter's sales — material, but a fraction of the ₩640 billion downside the company itself has flagged if the walkout runs its full five-day course. The union is seeking an average 14% wage increase, a one-time ₩30 million ($21,900) incentive payment per employee, performance bonuses equal to 20% of operating profit, and treasury share grants spread over three years, according to Seoul Economic Daily and The Korea Herald. Management has countered with a combined 6.2% increase to base and performance pay, calling the union's package "realistically difficult to accept," per the same outlets.

Industry & Historical Context

Samsung Biologics holds what it describes as the world's largest biomanufacturing footprint, with global capacity of 845,000 liters — 785,000 liters across Bio Campus I and II in Songdo and 60,000 liters at the Rockville, Maryland facility acquired in 2025 for $353 million, per the company's Q1 release. Plant 5, which adds 180,000 liters and is in ramp-up during Q1 2026, lifted the Korea footprint to its current scale, according to Samsung Biologics' own corporate communications and Pharma Manufacturing.

The South Korean CDMO sector has historically been characterized by relative labor stability compared with manufacturing peers in autos and shipbuilding, and Samsung Biologics in particular built its client roster on a reputation for uninterrupted supply. Fierce Pharma noted earlier this spring that the union's strike vote was the first material labor-relations test in the company's history. The current dispute follows thirteen rounds of bargaining and two CEO-union meetings between December and March that failed to bridge the wage gap, according to Seoul Economic Daily.

What to Watch

• Whether the May 4 mediation session under the Central Regional Employment and Labor Office produces a revised company offer above 6.2%, or whether management holds the line and the strike continues through May 5 as scheduled.
• Any disclosure to the Korea Exchange or DART (Korea's electronic disclosure system) revising the ₩150 billion loss figure, particularly if cancellation of additional biologic batches is required.
• Statements from Samsung Biologics' multinational customers regarding contingency arrangements; none have been made public as of this writing, per outlets reviewed.
• Whether the union expands actions beyond the May 1–5 window, or whether a tentative agreement allows Plants 1–4 to return to the "full utilization" status the company described in its Q1 2026 results.

Sources: - Yonhap News Agency — https://www.yna.co.kr/view/AKR20260501058400017 - Maeil Business Newspaper — https://www.mk.co.kr/news/it/12034145 - Maeil Business Newspaper — https://www.mk.co.kr/news/business/12034256 - Seoul Economic Daily — https://en.sedaily.com/finance/2026/05/01/samsung-biologics-suffers-150-billion-won-loss-from-first - Seoul Economic Daily — https://en.sedaily.com/finance/2026/05/02/samsung-biologics-strike-enters-day-two-as-labor-management - Seoul Economic Daily — https://en.sedaily.com/finance/2026/04/30/samsung-biologics-union-to-launch-first-ever-strike-may-1 - The Korea Herald — https://www.koreaherald.com/article/10729829 - Samsung Biologics Q1 2026 Results (PR Newswire) — https://www.prnewswire.com/news-releases/samsung-biologics-reports-first-quarter-2026-financial-results-302749940.html

By LineVest Markets Desk — May 2, 2026

This article is for informational purposes only and does not constitute investment advice.